853 related articles for article (PubMed ID: 7563511)
21. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
23. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
[TBL] [Abstract][Full Text] [Related]
24. Significance of serum free prostate specific antigen in the screening of prostate cancer.
Higashihara E; Nutahara K; Kojima M; Okegawa T; Miura I; Miyata A; Kato M; Sugisaki H; Tomaru T
J Urol; 1996 Dec; 156(6):1964-8. PubMed ID: 8911366
[TBL] [Abstract][Full Text] [Related]
25. [Circulating prostatic-specific antigen in benign hypertrophy and localized prostate cancer: can PSA be considered a screening examination for localized cancer?].
Perrin P; Francois O; Maquet JH; Bringeon G; Duteil P; Devonec M
Prog Urol; 1991 Jun; 1(3):419-31. PubMed ID: 1726943
[TBL] [Abstract][Full Text] [Related]
26. Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies?
Prestigiacomo AF; Stamey TA
J Urol; 1997 Jan; 157(1):189-94. PubMed ID: 8976248
[TBL] [Abstract][Full Text] [Related]
27. [Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases].
Kato M; Okada K
Hinyokika Kiyo; 1993 Mar; 39(3):221-3. PubMed ID: 7685140
[TBL] [Abstract][Full Text] [Related]
28. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
Prestigiacomo AF; Lilja H; Pettersson K; Wolfert RL; Stamey TA
J Urol; 1996 Aug; 156(2 Pt 1):350-4. PubMed ID: 8683677
[TBL] [Abstract][Full Text] [Related]
29. Effect of percent free prostate-specific antigen measurement on improving the specificity of serum prostate-specific antigen testing in Taiwanese patients.
Liao CH; Liu SP; Pu YS; Huang CY; Yu HJ; Chen J
J Formos Med Assoc; 2001 Feb; 100(2):113-9. PubMed ID: 11393098
[TBL] [Abstract][Full Text] [Related]
30. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH
J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612
[TBL] [Abstract][Full Text] [Related]
31. Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels.
Ornstein DK; Rao GS; Smith DS; Ratliff TL; Basler JW; Catalona WJ
J Urol; 1997 Jan; 157(1):195-8. PubMed ID: 8976249
[TBL] [Abstract][Full Text] [Related]
32. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.
Catalona WJ; Southwick PC; Slawin KM; Partin AW; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Loveland KG; Bray KR
Urology; 2000 Aug; 56(2):255-60. PubMed ID: 10925089
[TBL] [Abstract][Full Text] [Related]
33. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
[TBL] [Abstract][Full Text] [Related]
34. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.
Gann PH; Hennekens CH; Stampfer MJ
JAMA; 1995 Jan; 273(4):289-94. PubMed ID: 7529341
[TBL] [Abstract][Full Text] [Related]
35. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
[TBL] [Abstract][Full Text] [Related]
36. [Clinical assessment of free serum prostate specific antigen (PSA)].
Chautard D; Daver A; Bali B; Dardari J; Debras B; Colls P; Soret JY
Prog Urol; 1996 Jun; 6(3):368-74. PubMed ID: 8763691
[TBL] [Abstract][Full Text] [Related]
37. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies.
Catalona WJ; Beiser JA; Smith DS
J Urol; 1997 Dec; 158(6):2162-7. PubMed ID: 9366336
[TBL] [Abstract][Full Text] [Related]
38. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
[TBL] [Abstract][Full Text] [Related]
39. The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men.
Bangma CH; Kranse R; Blijenberg BG; Schröder FH
Urology; 1995 Dec; 46(6):773-8. PubMed ID: 7502414
[TBL] [Abstract][Full Text] [Related]
40. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
Akduman B; Alkibay T; Tuncel A; Bozkirli I
Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]